A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · OTHER · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 40
- Population
- FEMALE · 25 Years to 44 Years
- Duration
- 2019-10-02 to 2024-07-22
- Intervention
- Endotoxin; Placebo
- Comparator
- Placebo
- Outcomes measured
- Non-social (Monetary) Reward Response (Reward Learning and Sensitivity) — Baseline and post-injection (2.25 hrs); Non-social (Monetary) Reward Response (Reward Motivation) — Baseline and post-injection (2.1 hrs); Non-social (Monetary) Reward Response (Reward Sensitivity) — Baseline and post-injection (2.1 hrs); General Social Reward Response (Reward Sensitivity Via Emotional Dot Probe) — Baseline and post-injection (2.7 hrs); General Social Reward Response (Reward Sensitivity Via Face Morphing Task) — Baseline and post-injection (2.8 hrs); General Social Reward Response (Social Reward Motivation) — Baseline and post-injection (2 hrs); Depressed Mood Subscale of the Profile of Mood States (POMS) — Hourly, from pre-injection (T0) to 9 hours later (T9); Close Social Reward Response — Post-injection (2.9 hrs); Consummatory Daily Reward Response — 14 days (7 days pre-injection; 7 days post-injection).; Dopaminergic Activity — Baseline and post-injection (1.9 hrs); Anticipatory Daily Reward Response — 14 days (7 days pre-injection; 7 days post-injection).
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Sleep · 80%Title contains controlled term: sleep. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.